Dutch National Health Care Institute has published the reimbursement conditions for Flash Glucose Monitoring under basic health insurance

May 2018

Real Time Continuous Glucose Monitor (RTCGM) is a way for diabetic patients for continuous measurement of blood glucose levels. For certain groups of patients, it is reimbursed under basic health insurance. For the following groups of diabetic patients will also be eligible for reimbursement of Flash Glucose Monitoring (FGM):

Children with type I diabetes
Adults with high average blood glucode levels that can be adjusted poorly
Pregnant women with diabetes type I and II (excluding gestational diabetes)
Women with diabetes types I and II who have a pregnancy wish

Patients with type I diabetes who are suffering from severe hypoglycaemia and/or can not perceive it (so-called hypo-unawareness) are not eligible for FGM. RTCGM is a safer alternative for this group because of the alarm function and (possible) connection to an insulin pump.

See full details here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

Three projects awarded under the 2022 "Subsidy scheme for promising care" in the Netherlands

Mar 2022

On March 4, 2022, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced three projects which received a subsidy under the "Subsidy scheme for promising care" in 2022 for research of a new minimally invasive endoscopy-guided surgery in patients with spontaneous cerebral hemorrhage, oral immunotherapy in children to cure a food allergy and cutting the diaphragm band in chronic abdominal complaints.

Swedish MTP Council updated the recommendations on FreeStyle Libre

Mar 2022

In February 2022, Swedish Medical Technologies Product (MTP) Council issued an updated recommendation on FreeStyle Libre for continuous glucose monitoring in type 2 diabetes (T2D). The initial recommendations were published by NT Council in 2018 and updated by MTP Council in 2020 to include FreeStyle Libre 2. In the 2022 update, MTP Council decreased the Hba1c limit from 70 to 60 mmol/mol and added a statement on lifestyle changes and treatment optimization with non-insulin antidiabetic drugs.

Dutch Organization for Health Research and Development awarded eight projects under the "Healthcare Evaluation and Appropriate Use" program

Feb 2022

Dutch Organization for Health Research and Development, ZonMw awarded eight projects under the "Healthcare Evaluation and Appropriate Use" program, including two projects for geriatric care, two projects for cancer, per one project for cardiovascular, neurovascular, and dermatology care.

Closed-loop systems and the artificial pancreas for T1DM recommendation released in Scotland

Feb 2022

In January 2022, the Scottish Health Technology Group released a recommendation of the closed-loop systems and the artificial pancreas for type one diabetes mellitus. The limited use of closed-loop systems in routine clinical care makes it difficult to estimate device-related adverse event rates. No evidence was identified for artificial pancreas systems (multi-hormone closed-loop systems) available on the UK market.

New reimbursement framework for telemonitoring in France expected in July 2022

Feb 2022

On January 26, 2022, the HAS published standards for medical telemonitoring of four chronic pathologies (chronic respiratory failure, chronic heart failure, chronic renal failure, and diabetes). These standards must be met by technologies in order to be reimbursed by the new reimbursement framework for telemonitoring, which is expected to enter into force in July 2022.